Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting.
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? 8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well.
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP.
Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets.
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On? Arrowhead Pharmaceuticals Inc. (
NASDAQ: ARWR ) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (
NASDAQ: SRPT ). Here's what you need to know.
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q3 2024 ARWR stock results show that Arrowhead Pharma missed analyst estimates for earnings per share the third quarter of 2024.
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 Low priced stocks to buy for growth provide great value to investors in the $20 range and are expected to pop before 2025.
Why Arrowhead Pharmaceuticals (ARWR) Stock Is Seeing Blue Skies Arrowhead Pharmaceuticals shares are trading higher by more than 6% during Monday's session. The company announced that it presented preclinical data on ARO-INHBE.
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.
Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday? Arrowhead Pharmaceuticals announced Phase 3 PALISADE study results showing significant triglyceride reduction in familial chylomicronemia syndrome patients treated with plozasiran.
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet.
ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q2 2024 ARWR stock results show that Arrowhead Pharma missed analyst estimates for earnings per share the second quarter of 2024.
